A 73-Year-Old Man with Metastatic Urothelial Carcinoma

Arlene Siefker-Radtke, MD, discusses the nuanced treatment journey of a 73-year-old man with metastatic bladder cancer, highlighting the challenges and evolving strategies in his case.

Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.

The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.

Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.

Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.

Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.

Expert perspective on the impact of neuropathy on treatment choices in urothelial cancer, providing insight into identifying and managing peripheral neuropathy and exploring suitable treatment options.

Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.